Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 85,918 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 85,918 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Stock Up 2.1%

Shares of NASDAQ SION traded up $0.94 during trading hours on Thursday, reaching $44.94. 697,997 shares of the stock traded hands, compared to its average volume of 369,839. The company’s 50-day simple moving average is $40.18 and its two-hundred day simple moving average is $39.52. The company has a market capitalization of $2.03 billion, a P/E ratio of -23.28 and a beta of 1.33. Sionna Therapeutics, Inc. has a 52-week low of $16.38 and a 52-week high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, sell-side analysts forecast that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Freedom Capital cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Wall Street Zen downgraded shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Citizens Jmp restated a “market outperform” rating and set a $63.00 price target on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Finally, Wedbush initiated coverage on Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

Institutional Investors Weigh In On Sionna Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. UBS Group AG raised its position in shares of Sionna Therapeutics by 91.1% in the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after acquiring an additional 42,511 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Sionna Therapeutics by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares in the last quarter. Jennison Associates LLC grew its stake in Sionna Therapeutics by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after purchasing an additional 117,903 shares during the period. Eventide Asset Management LLC purchased a new stake in Sionna Therapeutics in the fourth quarter worth $26,290,000. Finally, Seven Grand Managers LLC bought a new position in Sionna Therapeutics in the fourth quarter worth $2,057,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.